Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
10-K
2022 FY
Annual report
8 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
28 Feb 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
Current reports
8-K
Departure of Directors or Certain Officers
29 Mar 24
8-K
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
28 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
8-K
Entry into a Material Definitive Agreement
9 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
8 Jan 24
8-K
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
20 Dec 23
8-K
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for Non-Active Progressive Multiple Sclerosis
8 Nov 23
8-K
Other Events
1 Nov 23
8-K
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
1 Nov 23
8-K
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following
19 Sep 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
9 Jan 24
S-8
Registration of securities for employees
3 Jan 24
424B3
Prospectus supplement
17 Nov 23
S-3
Shelf registration
1 Nov 23
POS AM
Prospectus update (post-effective amendment)
8 Feb 23
S-8
Registration of securities for employees
8 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
8 Feb 23
S-8
Registration of securities for employees
22 Jul 22
S-8
Registration of securities for employees
28 Feb 22
424B5
Prospectus supplement for primary offering
26 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
7 Apr 23
DEF 14A
Definitive proxy
7 Apr 23
PRE 14A
Preliminary proxy
24 Mar 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
28 May 21
DEFA14A
Additional proxy soliciting materials
22 Apr 21
Other
EFFECT
Notice of effectiveness
14 Nov 23
CORRESP
Correspondence with SEC
8 Nov 23
UPLOAD
Letter from SEC
6 Nov 23
UPLOAD
Letter from SEC
2 May 23
CORRESP
Correspondence with SEC
21 Apr 23
UPLOAD
Letter from SEC
27 Mar 23
EFFECT
Notice of effectiveness
13 Feb 23
CT ORDER
Confidential treatment order
11 Mar 19
CT ORDER
Confidential treatment order
20 Aug 18
CT ORDER
Confidential treatment order
19 Dec 16